ARTICLE | Clinical News
Qinprezo regulatory update
March 31, 2017 5:13 AM UTC
Sunesis submitted responses to Day 180 questions from EMA’s CHMP regarding an MAA for Qinprezo vosaroxin to treat relapsed or refractory acute myelogenous leukemia (AML) in patients ages ≥60. The comp...
BCIQ Target Profiles